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Abstract
Purpose: To determine whether HIV-1 produces microRNAs and elucidate whether these miRNAs can induce inflammatory
response in macrophages (independent of the conventional miRNA function in RNA interference) leading to chronic
immune activation.
Methods: Using sensitive quantitative Real Time RT-PCR and sequencing, we detected novel HIV-derived miRNAs in the sera
of HIV+ persons, and associated with exosomes. Release of TNFa by macrophages challenged with HIV miRNAs was
measured by ELISA.
Results: HIV infection of primary alveolar macrophages produced elevated levels of viral microRNAs vmiR88, vmiR99 and
vmiR-TAR in cell extracts and in exosome preparations from conditioned medium. Furthermore, these miRNAs were also
detected in exosome fraction of sera from HIV-infected persons. Importantly, vmiR88 and vmiR99 (but not vmiR-TAR)
stimulated human macrophage TNFa release, which is dependent on macrophage TLR8 expression. These data support a
potential role for HIV-derived vmiRNAs released from infected macrophages as contributing to chronic immune activation in
HIV-infected persons, and may represent a novel therapeutic target to limit AIDS pathogenesis.
Conclusion: Novel HIV vmiR88 and vmiR99 are present in the systemic circulation of HIV+ persons and could exhibit
biological function (independent of gene silencing) as ligands for TLR8 signaling that promote macrophage TNFa release,
and may contribute to chronic immune activation. Targeting novel HIV-derived miRNAs may represent a therapeutic
strategy to limit chronic immune activation and AIDS progression.
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Introduction
Persons infected with HIV-1 exhibit a state of chronic immune
activation, characterized by persistent and aberrant activation of
immune cells, and increased tissue levels of pro-inflammatory
mediators such as TNFa [1], that contributes to AIDS pathogen-
esis and may persist despite effective combined antiretroviral
treatment (cART) [2]. The causes of HIV-induced chronic
activation are not fully defined but likely include direct effects of
viral proteins and nucleic acids, innate and adaptive immune
responses to viral antigens, and translocation of microbial TLR
ligands from the gut to the systemic circulation [1,3,4]. Chronic
immune activation may play a role in the pathogenesis of AIDS,
since natural hosts of simian immunodeficiency virus (SIV) such as
sooty mangabeys fail to develop immunodeficiency and AIDS
despite high levels of viral replication, while exhibiting surprisingly
low levels of immune activation during the chronic stage of
infection [5]. In contrast, SIV infection of rhesus macaques and
other non-natural hosts results in high levels of systemic immune
activation, CD4+ T-cell depletion and rapid progression to AIDS
[6]. The absence of chronic immune activation in natural hosts
during SIV infection supports the important role of chronic
immune activation in AIDS pathogenesis.
MicroRNAs (miRNA; 18-22 nucleotide RNAs) are critical
regulators of diverse cellular functions including proliferation,
differentiation, metabolism, apoptosis and tumor progression
through the canonical function of miRNA in targeted gene
silencing by RNA interference (RNAi) [7]. However, miRNAs
may also regulate cellular function independent of targeted gene
silencing through stimulation of TLRs [8,9]. Altered miRNA
profiles are associated with progression or remission of inflamma-
tory disorders such as rheumatoid arthritis, systemic lupus
erythematosus and malignancies [10]. In addition, virus-encoded
miRNAs can dysregulate host cell function, such as Epstein Barr
virus (EBV) miRNA repression of host cell CXCL11/ITAC,
inducing EBV-associated lymphomas [11]. Viral miRNAs from
HIV have been described such as HIV vmiR-TAR [12–15], that
may influence host cell function through RNAi function [16], but
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directly stimulate bystander or recipient host cells has not been
established.
HIV-1 can infect macrophages, which may serve as a critical
HIV reservoir [17]. Although macrophage infection is generally
latent, activation can induce active replication from the HIV LTR
with release of infectious virions [18,19] and viral miRNA-TAR in
exosomes [16]. In the current study focusing on human
macrophages, we report on two novel HIV-derived miRNA (we
denote as vmiR88 and vmiR99) that are released by HIV-infected
macrophages and directly stimulate recipient macrophage early
TNFa release that is dependent in part on macrophage Toll-like
receptor 8 (TLR8). Furthermore, HIV-derived vmiRNA-mediated
signaling in macrophages promoting TNFa release is dependent
on high GU-content of HIV vmiRNA. Importantly, novel HIV
vmiRNAs associated with exosomes are detected in sera of
aviremic HIV-infected persons on stable cART. This is significant
because even in suppressed viral replication, HIV miRNAs are
produced since cART could not inhibit host RNA polymerase II
from transcribing HIV mRNA in infected cells [20,21]. Elevated
levels of HIV miRNAs in the circulation may activate innate
immune cells leading to immune activation and accelerate HIV-
associated co-morbidities. Finally, antagomirs complementary to
HIV-derived vmiRNAs dramatically reduce macrophage TNFa
release. These data support a potential role for HIV-derived
vmiRNAs from infected macrophages as contributing to chronic
immune activation in HIV-infected persons, and may represent a
novel therapeutic target to limit AIDS pathogenesis.
Materials and Methods
Reagents
HIV RNA oligoribonucleotide vmiR-TAR (Table 1) and novel
HIV RNA oligonucleotides vmiR88 and vmiR99 (Table 1) and
PCR primers were chemically synthesized (Integrated DNA
Technologies, Coralville, Iowa). ssRNA40/Lyovec and ssRN
A41/Lyovec were purchased from Imgenex (San Diego, CA).
Lipid A, protease inhibitor mixture, phorbol myristic acid (PMA)
and fetal calf serum were purchased from Sigma (St. Louis, MO).
Cytokine ELISA kits were from R&D Systems (Minneapolis, MN).
Oligonucleotides were complexed (50 mg/mL) in LyoVec accord-
ing to the manufacturer’s instructions (Imgenex, San Diego, CA)
prior to treating cells.
Human macrophage cell lines
Human promonocytic THP-1 cells, promyelocytic cell line
U937 (American Type Culture Collection), and HIV-infected U1
(HIV-infected U937 subclone) were obtained from the AIDS
Research and Reference Reagent Program (Bethesda, MD). Cell
lines were harvested during exponential growth phase, washed,
and then incubated in complete medium (RPMI 1640 containing
10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 units
of penicillin, and 100 mg/mL streptomycin), differentiated with
PMA (100 nM) for 24 h, adherent cells washed three times with
complete medium, and then cultured in medium containing
exosome-depleted FBS (System Biosciences, Mountain View,
California). Macrophage differentiation was confirmed by
CD11b expression and enhanced granularity by flow cytometry.
Cells in complete medium were stimulated with oligoribonucleo-
tide/LyoVec complexes or Lipid A (10 mg/mL) for 24 hr (37uC,
5% CO2), and conditioned medium was collected for TNFa
analysis by ELISA.
Human alveolar macrophages (AM)
Primary human AM cells were obtained from healthy 18–55
year old volunteers by bronchoalveolar lavage (BAL) using
standard techniques [22]. All procedures were performed with
written consent on adults following protocols approved by the Beth
Israel Deaconess Medical Center Institutional Review Board and
East Campus Committee on Clinical Investigations, New Proce-
dures and New Forms of Therapy. Healthy subjects were without
HIV risk factors and confirmed HIV seronegative by ELISA. BAL
cells were separated from the pooled alveolar lavage fluid, and AM
isolated by adherence [23]. AM viability was determined using
trypan blue dye exclusion, and demonstrated .95% positive
nonspecific esterase staining. AM in complete medium were
stimulated with oligoribonucleotide/LyoVec complexes or Lipid A
(10 mg/mL) for 24 hr (37uC, 5% CO2), and conditioned medium
was collected for TNFa analysis by ELISA.
Human sera
All procedures were performed with written consent on adults
following protocols approved by the Beth Israel Deaconess
Medical Center Institutional Review Board and East Campus
Committee on Clinical Investigations, New Procedures and New
Forms of Therapy. Archived sera from consenting asymptomatic
HIV+ persons with peripheral CD4+ T-lymphocytes counts ,
200 cells/mm
3 as detailed [24] were available for exosome
preparation and HIV miRNA detection.
Table 1. Oligoribonucleotides in quantitative Real Time RT-PCR and melting analysis of PCR products.
qPCR product TM (6C)
ORN Synthetic RNA sequence Observed Expected
vmiR88 59-PO4-G*A*G*U*G*C*U*U*C*A*A*G*U*A*G*U*G*U*G*mU*mG-39 70.560.2 71
vmiR99 59-PO4-G*U*A*G*U*G*U*G*U*G*C*C*C*G*U*C*U*G*U*mU*mG-39 70.260.3 70
vmiR-TAR 59-PO4-C*U*A*A*C*U*A*G*G*G*A*A*C*C*C*A*C*U*mG*mC-39 69.160.2 70
ssRNA40 59-PO4-G*C*C*C*G*U*C*U*G*U*U*G*U*G*U*G*A*C*mU*mC-39 70.560.4 71
antagomir88 59-mC*mA*mC*mA*mC*mA*mC*mU*mA*mC*mU*mU*mG*mA*mA* mG*mC*mA* mC*mU*mC -39 ––
antagomir99 59-mC*mA*mA*mC*mA*mG*mA*mC*mG*mG*mG*mC*mA*mC*mA*mC*mA*mC*mU*mA*mC-39 ––
‘‘*’’: phosphorothioate linkage
‘‘m’’: 29-O-methyl modification
doi:10.1371/journal.pone.0106006.t001
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TNFa measurements of cell-free macrophage cultured super-
natants were determined by ELISA (R&D Systems, Minneapolis,
Minnesota) according to the manufacturer’s instructions, and
absorbance was measured at 450 nm using an Emax ELISA plate
reader with multi-point data analysis using SoftMax Pro software
(Molecular Devices, Sunnyvale, California). The detection limit for
TNFa is 15.6 pg/mL. HIV-1 p24 antigen ELISA was from
Zeptometrix (Franklin, Massachusetts). All measurements were
performed in duplicate, and mean values of four measurements
were used for statistical analysis.
Time course analysis
THP-1 macrophages in complete medium were treated with
vmiR99 (1.0 mg/mL) formulated in LyoVec at the indicated time
points (37uC, 5% CO2). Conditioned medium was collected for
TNFa analysisbyELISA.ForanalysisofcytokinemRNA,adherent
cells were treated with Trizol (Applied Biosystems, Foster City,
California) and total RNA was prepared according to the
manufacturer’s instructions. First strand cDNA was synthesized
with the High Capacity RNA-to-cDNA kit (Applied Biosystems)
using a GeneAmp PCRSystem 9600 (PerkinElmer)setfor37uC for
60 min, 95uC for 5 min followed by 4uC. Real Time PCR was
performed in 20 mL reactions with SYBR Select Master Mix
(Applied Biosystems) using an ABI 7000 system programmed for
50uC (2 min), 95uC (2 min) followed by 40 cycles of 95uC (15 s)
denaturation, 55uC (15 s) annealing and 72uC (1 min) extension.
For cytokine expression analysis, qPCR of TNF cDNA was
performed using forward primer 59-TGCCTTGGCTCAGA-
CATGTTT-39 and reverse primer 59-GCTACATGGGAA-
CAGCCTATTGT-39 [25]. For normalization, GAPD was detect-
ed using forward primer 59- GGAGTCCACTGGCGTCTT-39
and reverse primer 59-AGGCTGTTGTCATACTTCTCAT-39
[26]. Relative quantitation of TNF gene expression was calculated
using the DDCT method [27].
TLR8 gene silencing in macrophages
To determine HIV miRNA-mediated signaling resulting in
TNFa release by macrophages, targeted TLR8 gene silencing in
human AM cells was performed as previously described [8].
Exosome isolation
Exosomes were isolated from sera and cell culture conditioned
medium using ExoQuick/ExoQuick-TC reagents (System Biosci-
ences, Mountain View, California), according to the manufactur-
er’s instructions. First flow-through fraction was analyzed for
exosomal marker using anti-CD63 primary antibody, anti-rabbit
HRP conjugate (System Biosciences) and ECL Select Western
blotting detection (Amersham).
RNA isolation
Total RNA was isolated from cells using the mirVana miRNA
Isolation Kit (Life Technologies, Foster City, California) according
to the manufacturer’s instructions. Total RNA was extracted from
exosomes using a SeraMir Exosome RNA Purification Column kit
(System Biosciences) according to the manufacturer’s instructions.
Total RNA concentration was measured by absorbance (260 nm),
and purity assessed by ratio of absorbance (260 nm and 280 nm)
and agarose gel electrophoresis.
Real Time RT-PCR analysis of miRNAs
First strand cDNA was synthesized from total RNA using a
GeneAmp PCR System 9600 (Perkin Elmer), and PCR amplifi-
cation was performed using the miRCURY LNA Universal RT
microRNA PCR system (Exiqon Inc., Woburn, Massachusetts) on
an ABI 7500 or ABI 7900HT Fast Real-Time PCR system
(Applied Biosystems). Chemically synthesized microRNAs were
used to standardize the assays in Absolute Quantitation mode.
RNA samples were pre-diluted to 5 mg/mL in nuclease-free water.
RNA is further diluted into a reverse transcriptase master mix
using the provided reagents (Reaction Buffer, synthetic spike-in
RNA UniSp6 and enzyme mix). The RT mixtures (20 mL/well)
are incubated for 60 min at 42uC, 5 min at 95uC, and the cDNA
products were cooled to 4uC. The miRCURY LNA Universal RT
microRNA PCR system (Exiqon Inc.) was used for Real Time
PCR analysis. Ten-fold serial dilutions of cDNA from synthetic
microRNA were prepared in nuclease-free water as standards.
cDNA from standards and samples were pre-diluted 80-fold into
nuclease-free water containing ROX dye (50 nM for ABI 7500
instrument or 500 nM for ABI 7900HT; Applied Biosystems). The
qPCR master mix was prepared from the provided reagents
(SYBR Green master mix and PCR primers). Diluted standards
and samples were combined with qPCR master mix and the plate
was centrifuged (15006g for 1 min at RT). The Real Time PCR
instrument was configured for absolute quantitation of each
amplicon. The instrument was set for 95uC for 10 min followed by
40 cycles of 95uC for 10 s and 60uC for 1 min (ramp rate=1.6uC/
s; 100% ramp rate in Standard mode) with detection of SYBR
Green fluorescence. After cycling, melt curves were monitored to
measure TM of each PCR product, and absolute quantitation of
microRNA from Real Time PCR was measured using Sequence
Detection System software (Applied Biosystems).
Cloning and sequencing of HIV miRNAs
PCR and cloning was used to confirm the sequences and ends of
the candidate HIV miRNAs. Total RNA was isolated from HIV-
infected cells and from exosomes and analyzed using miRCURY
LNA Universal RT microRNA PCR (Exiqon, Woburn, MA).
Selected qRT-PCR products were cloned into a pCR4-TOPO
vector and chemically transformed into One Shot TOP10
chemically competent Escherichia coli (Applied Biosystems). Trans-
formants bearing inserts were selected by spreading onto LB
ampicillin plates, and individual clones were grown in LB ampicillin
medium. Plasmids were purified using the PureLink Quick Plasmid
Miniprep Kit (Applied Biosystems), annealed with M13(-21)
forward primer (59-TGTAAAACGACGGCCAGT-39) or M13
reverse primer (59-CAGGAAACAGCTATGAC-39) followed by
extension and chain termination with fluorescent dye-labeled
dideoxy nucleotides. DNA sequencing in both directions was
analyzed by capillary electrophoresis using an ABI 3730 DNA
Analyzer (Dana Farber Molecular Biology Core facility, Boston,
MA) and Sequence Scanner Software (Applied Biosystems).
Statistical Analysis
Group comparisons were performed using two-way ANOVA
using Prism 6.0 software (GraphPad Software, San Diego, CA) or
one-way ANOVA with post hoc analysis by the Dunnett multiple
comparisons test using InStat 3.0 statistical software (GraphPad
Software, San Diego, CA). Results were expressed as mean6SEM.
Statistical significance was accepted for p,0.05.
Results
Identification of putative candidate miRNAs encoded by
HIV-1
We previously reported that HIV ssRNA40 induced macro-
phage TNFa release via TLR8-mediated signaling and chromatin
Novel HIV-1 MiRNAs Stimulate TNFa Release
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relative high guanosine + uridine (G+U) content [8]. Therefore,
we sought to determine whether HIV produces other small non-
coding RNAs such as miRNAs and ssRNA, which may be capable
of activating innate immune cells such as macrophages. First,
examining published Deep Sequencing data obtained from HIV-
infected cells revealed peaks of short RNA reads throughout the
HIV genome [14], and one of these peaks overlaps with the
ssRNA40 sequence. We identified a GU-rich tract in the HIV
LTR (Fig. 1A; nt#86-131 in R and U5 regions of HIV-1 BaL
strain [Genbank: AB221005], that encompasses a hot-spot of short
RNA reads indicative of possible mature microRNAs. We then
used UNAfold RNA folding software [28] to identify RNA
sequences featuring requisite short hairpin sequences (shRNA) in
the HIV LTR region and to calculate hairpin stability (Fig. 1B).
UNAfold identified three characteristic shRNA structures: vmir-
TAR (Fig. 1B, left, mature miR highlighted in black) previously
reported [14] in addition to two novel candidate shRNA, we
denote as vmir88 (Fig. 1B, middle, mature form highlighted in
blue) and vmir99 (Fig. 1B, right, mature form highlighted in red).
Thermodynamic calculations of the change in Gibbs free energy
for RNA folding (DG) were all less than zero (Fig. 1B) indicating
that all three alternative RNA hairpins can form spontaneously
(but mutually exclusively) in separate RNA molecules in the
presence of 1 M sodium ion. The calculated melting temperatures
(TM) for the three shRNA were all high (.53.8uC; Fig. 1B) and
substantially above physiological temperature (37uC), predicting
hairpin stability. Thus, using RNA folding analysis of published
HIV Deep Sequence of HIV LTR [14], we identified vmiR-TAR
(as previously reported) in addition to two novel mature viral
miRNA candidates, vmiR88 and vmiR99. After reverse transcrip-
tion using a degenerate primer with adapter and PCR amplifica-
tion, DNA sequencing of PCR products of cDNA from synthetic
vmiR88 shows full length sequence followed by the complement of
the primer adapter (15-nt poly(A) and Universal Tag sequence)
shown in Fig. 1C. Similarly, synthetic vmiR99 showed full length
sequence (missing the final G) followed by a 15-nt poly(A) and
Universal Tag sequence.
To validate and delineate the boundaries of mature viral
miRNAs, cell extracts and exosomal extracts were analyzed.
Sample cell extracts were in vitro-infected AM (healthy AM+
HIV), HIV-positive U1 macrophages stimulated by PMA (U1+
PMA). Exosomal extracts were from exosomes of HIV+ human
serum (HIV+ serum 10 b). Analysis of RNA from HIV-infected
U1 cells and in vitro infected AM cells revealed full-length vmiR88
and vmiR99 (Fig. 1C). One clone from U1 cells showed a missing
39-terminal G like synthetic vmiR99. Furthermore, analysis of
exosomal RNA exhibits full-length vmiR88 in clinical HIV+
serum of an asymptomatic person and in in vitro infected AM.
However, exosomal miRNAs also demonstrated some longer
variants. Exosomes from PMA-stimulated U1 cells produced
vmiR88 with a 39-terminal 15-nt HIV RNA extension (Fig. 1C)
and vmiR99 with a 39-terminal 13-nt HIV RNA extension
(Fig. 1C). Analysis of vmiRs in exosomes from HIV+ serum of an
asymptomatic person exhibited sequences from vmiR99 with four
39 nucleotides substituted for 9 nt of HIV RNA (Fig. 1C).
Observed sequencing of vmiR88 or vmiR99 have differing 39
termini followed by polyadenylation that may have occurred in
vivo and/or prior to first strand cDNA synthesis by in vitro
polyadenylation. The 39 termini of vmiR88 and vmiR99 lie
downstream from the classical poly A site (Fig. 1C). Moreover, the
observed vmiR88 sequence spans the classical poly(A) site [29],
suggesting that a mechanism of alternative RNA folding and
cleavage produces mature vmiR88. Interestingly, vmir88 is an
extended shRNA hairpin structure compared to HIV-1 poly(A)
hairpin, and the HIV-1 poly(A) hairpin was shown to regulate
polyadenylation [30]. Observation of vmiR99 sequences from
HIV-infected samples suggests a similar mechanism for vmiR99
biogenesis.
Candidate miRNAs have high G+U base composition and
are highly conserved in the HIV genome
We recently demonstrated that high G+U content of ssRNA40
determined biological activity to stimulate macrophage TNFa
release [8]. In addition, ssRNAs rich in G+U sequence have been
shown to induce cytokines in plasmacytoid cells and peripheral
blood mononuclear cells [31]. The potential importance of the G+
U content is further suggested by high G+U sequence conservation
despite high HIV mutation rate, based on analysis of the Los
Alamos National Laboratories’ HIV Sequence Database for HIV
subtypes A-J [http://www.hiv.lanl.gov/content/sequence/HIV/
mainpage.html]. The consensus sequence of the 46-nt GU-rich
tract is strongly conserved with two or fewer mismatches in 84% of
HIV genomic isolates (196 independent isolate sequences exam-
ined; Fig. 2A) of which 37% are completely identical to the
consensus. Therefore, we next evaluated the GU content and
sequence conservation of the candidate miRNAs. By scanning
every miRNA-sized (21-bp) segment in the genomic RNA of HIV-
1 BaL, we determined that these segments have base compositions
of 46.5611.8% G+U. TAR miRNA with only one UG is
relatively GU-poor (35% G+U; Fig.2C). However, within the R
and U5 regions, our two candidate mature miRs have very high
G+U base compositions (vmiR88, 71% G+U and vmiR99, 76%
G+U), which were over two standard deviations above average for
HIV-1 BaL strain (Fig. 2B). Moreover, the individual candidate
miRNAs are highly conserved. VmiR99 is identical to 82% of
genomic HIV sequences and has two or fewer mismatches in 96%
of genomic sequences from 254 independent isolates (Fig. 2B).
Similarly, vmiR88 is identical to 45% of genomic HIV sequences
and has 0-2 mismatches in 82% of genomic sequences from 201
independent isolates (Fig. 2B). Thus, in addition to requisite
hairpin structure, our novel mature miRNA candidates vmiR88
and vmiR99 were selected for biological investigation due to their
relatively high G+U base composition.
Sensitive Real Time qRT-PCR detects HIV miRNAs
Whether HIV miRNAs are released into biological specimens
remains controversial, and may be in part be attributable to
limitations in detection methodology. Recently reports describe
HIV-produced miRNAs although at lower levels than both
cellular miRNAs and miRNA produced by other viruses [32].
Deep Sequencing technology, which detects and sequences single
RNA molecules, has recently identified numerous small RNAs of
low abundance encoded throughout HIV genome including
detection of HIV miRNA-TAR [14].
To address these limitations of detection, we developed a highly
sensitive Real Time PCR method enhanced by Locked Nucleic
Acid (LNA) primers for single-copy detection of HIV miRNAs.
The assays were standardized using chemically synthesized
miRNAs for absolute quantitation. Synthetic miRNA standards
were reverse transcribed into cDNA, and Real Time PCR was
performed using 10-fold serial dilutions of cDNA. This provided a
concentration-dependent lag that precedes discernable exponen-
tial amplification as shown by monitoring normalized fluorescence
intensity (Fig. 2D, F, H). The standard curves for vmiR-TAR,
vmiR88, vmiR99 and ssRNA40 (Fig. 2E, G, I) demonstrate a
seven-log analytical range including single-copy detection (log
(copies/well)=0). Thermal denaturation provided experimental
Novel HIV-1 MiRNAs Stimulate TNFa Release
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e106006Figure 1. Identification of candidate miRNAs encoded by GU-rich tract in HIV LTR and is highly conserved in HIV-1. A: Small RNAs
processed from HIV-1 LTR region observed by SOLiD Deep Sequencing. Left peak shows small RNAs derived from TAR stem (miR TAR). Right peak
shows a hotspot for small RNAs derived from R and U5 stem region. The GU-rich tract (46 nt) encodes a family of viral miRs including vmiR88 and
vmiR99. Modified from [14]. B: shRNA mirs are intermediates in biogenesis of mature vmiRs. shRNA reported for 43/9175 TAR (left). UNAFold software
predicts folding of shRNAs vmir88 (middle) and vmir99 (right), which suggests the structures of intermediates in the biogenesis of the mature vmiR-
TAR (black rectangle), vmiR88 (blue rectangle) and vmiR99 (red rectangle). UNAFold’s thermodynamic calculations predict that all three shRNAs fold
spontaneously (DG,0) into stable hairpins (high melting temperature, TM.53.8uCi n1 MN a
+). C: To delineate the boundaries and sequences of
mature viral miRNAs, cell extracts and exosomal extracts were analyzed. Sample cell extracts were in vitro-infected AM (healthy AM+HIV), HIV-positive
U1 macrophages stimulated by PMA (U1+PMA). Exosomal extracts were from exosomes of HIV+ human serum (HIV+ serum 10 b). Total RNA was
Novel HIV-1 MiRNAs Stimulate TNFa Release
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e106006amplified by qRT-PCR, cloned into pCR4-TOPO vector and DNA was sequenced. Sequences of vmiR88 and vmiR99 PCR products were aligned with
sequences of plasmid (vector) and HIV-BaL strain. The polyadenylation signal (PA signal) and polyadenylation site (PA site) were reported [29,36].
doi:10.1371/journal.pone.0106006.g001
Figure 2. Sequence alignment of HIV vmiRs with consensus genomic sequence from HIV-1 subtypes and absolute quantitation of
miRNAs by Real Time RT-PCR. A: Alignment of vmiR sequences of GU-rich tract is consistent with consensus genomic sequence from HIV-1
subtypes A-J, 533 isolates. B: VmiR99 is 90–100% identical to 96% of HIV-1 sequences. Sequences within the GU tract, vmiR88, vmiR99 and ssRNA40
were aligned with 196, 201, 254 and 272 genome sequences, respectively. C: Genomic RNA of HIV-1 BaL strain was scanned for every 21-bp RNA
segment and the distribution of base compositions (46.5611.8% G+U) is shown. VmiR-TAR is GU-poor (35%). VmiR88 and vmiR99 are GU-rich (71%
and 76% G+U, respectively). Absolute quantitation of miRNAs was determined by Real Time RT-PCR. After first strand cDNA synthesis, amplification
(D, F, H) and absolute quantitation (E, G, I) of vmiR-TAR (D–E) vmiR88 (F–G), vmiR99 (H–I) and RNA40 (I) was standardized using synthetic miR
oligonucleotides in the miRCURY LNA Universal RT microRNA PCR method (Exiqon) on an ABI 7900HT FAST Real Time PCR system. DRn is the change
in normalized reporter fluorescence intensity. CT is the threshold cycle in which the amplification curve crosses the dashed horizontal line. Data depict
a representative experiment done in duplicate.
doi:10.1371/journal.pone.0106006.g002
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in good agreement with the manufacturer’s expected values
(Table 1). Thus, sensitive LNA-enhanced Real Time PCR
methodology offers a powerful approach to detect and analyze
HIV-produced miRNAs of low abundance.
Novel HIV-produced miRNAs detected in HIV-infected
human macrophages
Prior studies demonstrate release of HIV-produced vmiR-TAR
by HIV-infected cells [12–15]. In the current study, vmiR-TAR
was not detected in cell extracts of differentiated unstimulated
HIV+U1 human macrophages, or the parent (non-HIV infected)
U937 macrophages (Fig. 3B). However, following PMA stimula-
tion, abundant HIV vmiR-TAR was detected in cell extracts from
HIV+U1 macrophages. In addition, abundant novel HIV vmiR99
was detected in PMA-stimulated HIV+U1 macrophages, at levels
comparable to vmiR-TAR (Fig. 3B). Using clinically relevant
primary human alveolar macrophages, both HIV-produced vmiR-
TAR and the novel vmiR99 were detected in cell extracts from
alveolar macrophages from an asymptomatic HIV+ person, but
only following PMA stimulation, and both were detected at
relatively low copy numbers (Fig 3C). In vitro HIV infection of
alveolar macrophages from healthy volunteers, demonstrates HIV
p24 antigen at 16 d post infection, whereas mock infection
produced detectable p24 antigen (Fig. 3A). Importantly, at day 16
following in vitro HIV infection, cell extracts yielded abundant
expression of vmiR-TAR in addition to both novel HIV-produced
vmiR88 and vmiR99, but not the control oligoribonucleotide,
ssRNA40 (Fig. 3C). Thus, in addition to HIV-derived vmiR-TAR,
HIV-infected macrophages produce abundant novel HIV-vmiR88
and vmiR99.
Novel HIV-1 miRNAs stimulate macrophage TNFa release
through TLR8 activation
HIV-produced vmiR-TAR can influence host cell function
through canonical gene silencing in RNAi [33], but whether HIV-
derived viral miRNA can directly stimulate macrophage responses
has not been established. G+U-rich ssRNA40 has pro-inflamma-
tory activity in macrophages [8]. Therefore, we tested whether
vmiR88 and vmiR99 (viral miRNAs with high G+U content) can
induce cytokine release. Human AM incubated with vmiR-TAR
did not result in significant release of TNFa (Fig. 3D). In contrast,
incubation with novel vmiR88 and vmiR99 resulted in robust
release of TNFa in a concentration-dependent manner (Fig. 3D),
with optimal TNFa release at 1 mg/mL. VmiR99 is notably more
potent than vmiR88 in eliciting TNFa release in primary alveolar
macrophages (Fig. 3D), although the uptake efficiency of LyoVec-
vmiR complexes was not measured. This potency difference may
be due to the relatively higher G+U content of vmiR99 (Table 1),
as stimulation with a control molecule G+U-rich ssRNA40 also
promoted macrophage TNFa release, whereas the inactive variant
(GU-deficient ssRNA41) did not (Fig.3D). Importantly, on a molar
basis, vmiR88 and vmiR99 stimulated TNFa release more
potently than lipid A (Gram-negative bacteria-derived TLR4
ligand implicated in the gut translocation hypothesis of HIV
chronic immune activation). VmiR99-mediated macrophage
TNFa release was significantly inhibited in the presence of specific
antagomir either pre-annealed to vmiR99 before addition to cells
or by pre-treatment of macrophages with antagomir followed by
vmiR99 challenge (Fig. 3E).
We recently demonstrated that HIV-derived ssRNA40 elicited
TLR8-dependent release of TNFa [8]. To further study the
mechanism of this pro-inflammatory function of HIV vmiRs, we
investigated whether vmiRs also elicit TNFa response that is
mediated by TLR8. Gene-targeted silencing of TLR8 confirmed
that vmiR99-stimulated macrophage TNFa release is dependent
in part on macrophage TLR8 expression (Fig. 3F). As expected,
the TLR4 agonist Lipid A stimulated TNFa release without
regard to knockdown of TLR8 (Fig. 3F). Western blot confirms
that TLR8 protein was decreased in siTLR8-treated AM
compared to non-silencing siRNA-treated AM, and uniform
extract loading was demonstrated by anti-b-actin antibody
(Fig. 3F). These data demonstrate that novel HIV-produced
vmiR99 can directly stimulate signaling in macrophages that
results in TNFa release and is dependent on macrophage
endosomal TLR8.
HIV vmiRNA-mediated macrophage TNFa release is rapid
and inhibited by antagomirs
To determine the time course for HIV vmiRNA-mediated
macrophage TNFa release, human THP-1 macrophages were
incubated with vmiR99 and TNFa release measured in cell culture
supernatants over 2–24 h. In response to vmiR99, half-maximal
TNFa release was observed by 2 h with maximal release by 6 h,
which remained stable through 24 h (Fig. 4A). By contrast
vmiR99-induced gene expression was slow and transient; induc-
tion of TNF mRNA did not exhibit a statistically significant
increase until 12 hr followed by a decline to basal expression by
24 h (Fig. 4A). Thus, vmiR99-mediated human macrophage
TNFa release was rapid and consistent with release of pre-formed
TNFa protein, suggesting direct stimulation rather than requiring
vmiR99-targeted gene transcription, translation, post-translational
modification, trafficking, externalization of TNFa protein or
vmiR99-targeted silencing of genes regulating the pathway leading
to activation of TNFa release.
Pre-treatment with antagomir (1 h) followed by vmiR treatment
(perfectly complementary vmiR/antagomir pairs are strongly
favored to form full-length 21-nt dsRNA duplexes (vmiR88/
antagomir88 and vmiR99/antagomir99; DG=231.0 and 2
38.4 kcal/mole, respectively) inhibited TNFa release (Fig. 4B).
Surprisingly, half-complementary vmiR/antagomir pairs that can
form half-length 10-nt dsRNA duplexes (vmiR88/antagomir99
and vmiR99/antagomir88; both with DG=213.8 kcal/mole)
were inhibited to the same extent as perfectly complementary
pairs (Fig. 4B). Further, ssRNA40/antagomir88 have minimal
complementarity (6-nt dsRNA duplex) but TNFa release is
inhibited as well as perfectly complementary vmiR/antagomir
pairs. Because an ssRNA40/antagomir88 duplex has poor
thermodynamic stability (DG=28.6 kcal/mole), inhibition by
duplexing the signaling ligand (ssRNA40) can be ruled out in this
case, suggesting an alternative mechanism of inhibition. These
data suggest that targeted duplexing of vmiRNA with specific
antagomirs is not essential to impairing vmiR88 or vmiR99-
mediated TNFa release, but may require alternate mechanisms
such as competitive binding to the ligand-binding site of cellular
receptors such as TLR8.
HIV vmiRNA-mediated macrophage TNFa release is
dependent on vmiRNA sequence motifs
Small TLR8 agonists such as R848, CL075 and CL097 [34] are
adenine (A) analogs, suggesting that adenine residues may be
functional ligands of TLR8. However, ssRNA41 (an adenine-rich
analogue of ssRNA40, with all U residues substituted with A) fails
to stimulate TNFa release through TLR8 [8]. To further define
the role of adenine in vmiR99-mediated signaling in macrophages
resulting in TNFa release, we generated variants of vmiR88 and
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U residues with A residues in selected blocks or along the entire
vmiRNA (Fig. 4C). Macrophage TNFa release was minimal in
unstimulated cells or in response to ssRNA41 (negative control),
but robust in response to vmiR88, vmiR99 and ssRNA40 (positive
control) stimulated TNFa release. Surprisingly, substitution of all
U residues to A in vmiR99 (U13-31A) stimulated a statistically
significant elevation of TNFa release compared to vmiR99
(Fig. 4C). Mutations of the middle block (U13-20A modification)
of either vmiR88 or vmiR99 seemingly resulted in a modest
increase in macrophage TNFa release, which was not statistically
significant (Fig. 4C). Substitution of all U residues to A in vmiR88
(U4-20A) induced signaling that appeared to have decreased
TNFa release compared to native vmiR88, but this was not
statistically significant (Fig. 4C). These data demonstrate that
specific nucleotide sequence and A-base composition, rather than
Figure 3. Novel HIV-produced miRNAs are detected in HIV-infected human macrophages, and stimulate macrophage TNFa release
in vitro.A : AM were exposed to HIV-1 particles, BaL strain (10 ng/0.1 mL Gag p24/106 cells for 3 h) and washed. HIV p24 levels were assayed by
ELISA. Data presented are AM infected with HIV-1 done in duplicate (n=4 subjects). Quantitative PCR measurement of HIV miRNA from cell extracts
of adherent (B) human macrophage cell lines U937 and HIV+U1, and (C) human primary alveolar macrophages (established in vitro HIV infection, or
from asymptomatic HIV+ person), incubated in the absence or presence of PMA for 24 hr. D: TNFa measurement (ELISA) in culture supernatants in
AM from healthy volunteers following 24 h incubation with HIV miRNA (vmiR-TAR, vmiR88, or vmir99) over a concentration range (0.01–1.0 mg/mL),
lipid A (10 mg/mL), or control GU-rich ssRNA40 or AU-rich ssRNA41. E: TNFa measurement (ELISA) in culture supernatants from adherent human
alveolar macrophages from healthy volunteers was treated with antagomir99 (1 h) followed by vmiR99 (24 h). At right, adherent AM were treated
with pre-annealed antagomir99NvmiR99 duplex (**) for 24 h. F: TNFa measurement (ELISA) in culture supernatants from adherent human alveolar
macrophages from healthy volunteers, in the presence of targeted TLR8 gene silencing (TLR8 siRNA) compared to control non-silencing RNAi (Control
siRNA) following 24 h incubation with novel HIV vmiR99 (1.0 mg/mL in LyoVec), Lipid A (10 mg/mL) or unstimulated (US; LyoVec vehicle control). Cell
extracts were analyzed by Western blot for TLR8 knockdown using anti-TLR8 antibody and for well loading using anti-b-actin antibody. Data for each
figure reflect a minimum of 4 experiments, performed in duplicate. *, p,0.05.
doi:10.1371/journal.pone.0106006.g003
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efficiency of LyoVec-vmiR complexes was not measured. The
apparent potency of vmiRs to signal TNFa release by THP-1
macrophages (Fig. 4B, C) is lower than for AM (Fig. 3D), which
could be due to different efficiencies of LyoVec-vmiR uptake in
the two cell types.
Novel HIV-produced miRNAs are released by infected
macrophages and associated with exosomes
A recent report demonstrates that HIV-derived vmiR-TAR
released by HIV-infected cells was contained within exosomes
[16]. Consistent with these observations, in the current study
vmiR-TAR was detected in exosomal preparations from HIV+U1
human macrophages, but only following PMA stimulation
(Fig. 5A). Importantly, HIV+U1 macrophages also released novel
vmiR99, associated with exosomal fraction, at levels comparable
to vmiR-TAR. There was no significant HIV-produced miRNA in
the absence of PMA stimulation. In contrast, alveolar macro-
phages from HIV+ person exhibited robust constitutive release of
vmiR-TAR associated with exosomes, but release of novel vmiR99
was limited, even following PMA stimulation. In comparison, in
vitro HIV infection of primary alveolar macrophages from healthy
persons resulted in release of vmiR-TAR and novel vmiR88 and
Figure 4. Viral miRNAs stimulate THP-1 macrophages to release TNFa rapidly in a vmiR sequence-dependent manner, and release is
inhibited by antagomirs. A: THP-1 macrophages were treated with vmiR99 (1.0 mg/mL) at the indicated time points (hr) or with Lipid A or
ssRNA40 (24 h). Conditioned medium was analyzed by ELISA. Total RNA was isolated from cell extracts, and expression of TNF (normalized by GAPD)
was analyzed by qRT-PCR. Results are the average of three independent experiments done in duplicate. B: THP-1 macrophages were pre-treated with
antagomir (5.0 mg/mL for 1 h) followed by treatment with ssRNA40 (2.5 mg/mL), vmiR88 (5.0 mg/mL) or vmiR99 (5.0 mg/mL for 24 h), and conditioned
medium analyzed by ELISA. C: Sequence variants of vmiR88 and vmiR99 can elicit TNFa release by THP-1 macrophages. Variants of vmiR88 or vmiR99
were chemically synthesized by substituting the uridine residues of U-rich motifs (boxed regions) for adenine residues. VmiRs and variants (5.0 mg/
mL) were applied to cells for 24 h. Supernatants of conditioned medium were assayed for TNFa by ELISA. *, p,0.05.
doi:10.1371/journal.pone.0106006.g004
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strate that in addition to vmiR-TAR, HIV-infected macrophages
release novel vmiR88 and vmiR99 associated with exosomes.
Detection of novel HIV miRNA in exosome fraction of
sera from HIV-infected persons
HIV TAR miRNA is associated with exosomes from the sera of
HIV-infected persons [16], but whether other HIV vmiRNAs are
present in sera has not been determined. In the current study,
using sensitive quantitative RT-PCR, we detected HIV vmiR-
TAR as well as novel vmiR88 and vmiR99 associated with the
exosomal fraction of sera in the majority of HIV+ persons
(Fig. 5C). The levels of vmiR88 and vmiR99 occasionally exceed
those of vmiR-TAR, although there was extensive biological
variability (Fig. 5C). Of 14 serum samples containing exosomes
obtained from 13 HIV+ individuals at our clinic, at least one of
these HIV miRNAs was detected from exosomal preparations
from 12/13 (92%) of HIV+ individuals. Taken together, these data
demonstrate that vmiR-TAR and novel HIV-produced miRNAs
are present in exosomes from sera of HIV+ persons.
Exosomes from aviremic HIV+ serum and from
conditioned medium of HIV-infected cells stimulate TNFa
release
Exosomes from HIV-infected serum and healthy serum were
prepared using ExoQuick reagent. Serum exosomes from patient
#9 were positive for vmiR99 and vmiR-TAR by qRT-PCR
(Fig. 5C). Treatment of THP-1 macrophages with exosomes from
healthy serum resulted in no stimulation of TNFa release
compared to untreated macrophages (Fig. 5D). However, treat-
ment by positive control (synthetic vmiR99) or by exosomes from
HIV
+ serum (patient #9) resulted in a significant increase in
TNFa release (Fig. 5D). To confirm these results, we isolated
exosomes from HIV-infected cell lines grown in medium
containing exosome-depleted FBS (System Biosciences, Mountain
View, CA). Exosomes isolated from U1 macrophages exhibit
vmiR99 and vmiR-TAR by qRT-PCR (Fig. 5A). Conditioned
medium collected from healthy parental U937 macrophages did
not elicit additional TNFa release by THP-1 macrophages
compared to untreated control (Fig. 5E). By contrast, synthetic
vmiR99 and exosomes isolated from conditioned medium of U1
macrophages (each cell bearing two copies of integrated HIV-1)
stimulated THP-1 macrophages to release TNFa (Fig. 5E). These
results show that exosomes bearing viral miRNAs vmiR99 and
vmiR-TAR can elicit TNFa release by macrophages.
Discussion
These data demonstrate the production of HIV-derived
miRNAs by human macrophages in vitro, including vmiR-TAR
(vmiR43/9175) as previously reported [14,33] in addition to novel
HIV-derived vmiR88 and vmiR99. Novel HIV vmiR88 and
vmiR99 are produced by HIV-infected human macrophage cell
lines, human alveolar macrophages following in vitro HIV
infection, and by alveolar macrophages from asymptomatic
HIV-infected persons with advanced HIV infection (peripheral
blood CD4+ T-lymphocyte count ,200 cells/mm
3), especially
following PMA stimulation. Full-length sequences of vmiR88 and
vmiR99 expressed in infected cells were confirmed. Exosome
preparations harbored full-length vmiR88 as well as longer
variants of vmiR88 and vmiR99 bearing 39 extensions of viral
sequence. Furthermore, incubation of uninfected recipient mac-
rophages with exogenous vmiR88 or vmiR99 stimulate a pathway
in macrophages that elicits TNFa release. The mechanism of these
pro-inflammatory miRNAs was not due to the role of miRNA in
targeted gene silencing by RNA interference. Instead, the HIV-
derived miRNAs directly stimulated a signaling pathway in
macrophages resulting in TNFa release, a process that was
dependent partly on G+U base composition of the miRNA, and
partly on macrophage TLR8 expression. Using a flow cytometry
based fluorescence resonance energy transfer (FC-FRET) assay,
we demonstrated binding of ssRNA40 to human TLR8 [35].
Furthermore, TNFa release was inhibited by antagomir88 and
antagomir99 even with partial or little complementarity to the
ssRNA ligand, suggesting that these antagomirs may function
more strongly as receptor antagonists relative to their intended
function as ligand antagonists. Finally, novel HIV vmiRNAs are
detected in sera of HIV-infected persons, and associated with
exosomal fraction. Biological significance is suggested by the
finding that exosomes from serum of an HIV-infected aviremic
person as well as exosomes from HIV-infected U1 macrophages
elicit a pro-inflammatory response (TNFa release) by human
macrophages, whereas exosomes from healthy serum and from
uninfected parental macrophages did not stimulate TNFa release.
These data support a potential role for novel HIV-derived
vmiRNAs from macrophages as contributing to chronic immune
activation in HIV-infected persons.
This is the first study to detect novel HIV vmiR88 and vmiR99
in biological samples, and their association with exosomes from
human macrophages in vitro and the clinical relevance of vmiR88
and vmiR99 through detection in exosomal preparations from the
sera of HIV+ persons, which suggests the possibility of exosome-
mediated delivery of pro-inflammatory viral miRNAs to uninfect-
ed bystander cells. Highly sensitive detection was possible using an
advanced qRT-PCR methodology enhanced with LNA primer
technology. Sequences of qRT-PCR products of vmiR88 and
vmiR99 from cell extracts were confirmed and exhibited 39
termini that are distinct from the reported 39-terminal polyade-
nylation site of HIV genomic RNA [29,36]. Longer variants of
vmiR88 and vmiR99 were detected in exosome preparations,
which may be related to selective miRNA packaging into
exosomes or have unknown functions.
The mechanism for novel vmiR88- and vmiR99-induced
macrophage TNFa release was dependent in part on high G+U
base compositions of the miRNA, as vmiR-TAR (35% G+U) and
control ssRNA41 (absent G) failed to stimulate signaling resulting
in macrophage TNFa release, whereas vmiR88 (71% G+U),
vimR99 (76% G+U) and positive control ssRNA40 (65% G+U)
stimulated macrophage TNFa release, although the minimal
requirement was not established in the current study. For
comparison, genomic RNA of HIV-1 BaL strain has 47% G+U
composition. Importantly, the observation that the molar potency
of vmiR99 to induce macrophage TNFa exceeded that for the
endotoxin component lipid A by 40-fold, suggesting that even low
concentrations of vmiR88 and vmiR99 may significantly contrib-
ute to signaling in macrophages that result in downstream pro-
inflammatory cytokine release.
Although vmiR88 and vmiR99 exhibit sequence overlap, each
demonstrates distinct function. In the current study each novel
vmiRNA induces macrophage signaling culminating in TNFa
release, but vmiR99 more potently than vmiR88. Also, URA
mutations of vmiR99 modifies the potency for macrophage TNFa
release; substitution of every U to A along the entire vmiR99
sequence enhances macrophage TNFa release, which suggests
that G+U content may contribute to stimulation of macrophages
resulting in TNFa release, but other molecular sequences may be
more important. Indeed TLR8 is stimulated by ssRNA molecules
of many different sequences with various potencies [31]. Prior
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secondary structure may be more critical to RNA function, with
the poly(A) hairpin [29,36] providing essential stability [30,37]. In
addition, the striking observation that both vmiR88 and vmiR99
were identified from a highly conserved GU tract in a virus with
an exceptionally high mutation rate suggests critical, perhaps
essential, functions for these HIV-derived miRNAs. Although
vmiR-TAR may modulate cellular apoptosis, additional roles of
Figure 5. Novel HIV-produced miRNAs are released by HIV-infected human macrophages and associated with exosomes in vitro,
and detected in sera from asymptomatic HIV+ persons. Quantitative PCR measurement of HIV miRNA from exosomal preparation of cultured
supernatants from adherent (A) human macrophage cell lines U937 and HIV+U1, and (B) human alveolar macrophages (established in vitro HIV
infection, or from asymptomatic HIV+ person), incubated in the absence or presence of PMA for 24 h. Western blot immediately beneath each bar
graph demonstrates exosomal marker CD63 associated with corresponding sample. Data reflect a minimum of 4 experiments performed in duplicate.
(C) Quantitative PCR measurement of HIV miRNA in exosomal preparations from archived sera of asymptomatic HIV+ persons with peripheral blood
CD4+ T-lymphocyte count ,200 cells/mm
3. Data reflect measurements performed in duplicate. Results shown include exosome preparations
isolated from HIV+ sera (n=14) sampled from HIV+ patients (numbered 1–13). Serum samples ‘‘10a’’ and ‘‘10b’’ were drawn on separate days from
Patient 10. (D) Exosomes were isolated from serum (HIV
+ serum from Patient 9 or healthy serum) using ExoQuick-TC reagent and resuspended in the
original volume of PBS (divalent cation-free). THP-1 macrophages cultured in medium (1.0 mL) were treated with 10 mL of exosome suspension (24 h,
37uC, 5% CO2). (E) THP-1 macrophages were treated (24 h) with 500 mL of conditioned medium (healthy parental U937 macrophages that had been
cultured 6 d) or medium-suspended exosomes that had been isolated from 500 mL HIV
+ conditioned medium (U1 macrophages cultured 6 d).
Conditioned medium was analyzed by ELISA for TNFa.* ,p ,0.05.
doi:10.1371/journal.pone.0106006.g005
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fold into different secondary structures during transcription, which
may explain how miRNA biogenesis can yield distinct vmiR88
and vmiR99 products of overlapping primary sequence by
processing alternatively-folded transcripts. This idea is prece-
dented by bacterial attenuators, which are the microbial RNA
sequences that form alternative, mutually exclusive hairpin loops
(terminator hairpins or anti-terminator hairpins) to regulate
expression via transcriptional pausing mechanism according to
physiological conditions [38–40]. Similarly, it was recently
reported that during transcription of the HIV LTR, two host
enzymes of the RNAi pathway (DROSHA, DGCR8) and other
factors cause pausing of RNA polymerase II and endonucleolytic
cleavage in the TAR hairpin [41], but that study did not include
the immediately downstream sequences (vmir88 and vmir99,
alternative hairpins of comparable thermodynamic stability) and
could not study vmiR88 and vmiR99 miRNA biogenesis.
Results from the current study support an important biological
function for these novel HIV-derived miRNAs other than RNAi
function. In general, miRNA function is characterized as RNA
interference through targeted gene silencing of mRNAs at the
translational level [42,43]. However, the observed macrophage
response to vmiR88 and vmiR99 was much faster than would be
expected for miRNA RNAi function, and rather supports other
important biological miRNA function(s), eg. serving as direct
agonists for cell signaling, such as ligands of TLR8. VmiR99-
stimulated TNFa release was very rapid with .50% released by
2 h and maximal release by 6 h, which is much faster than the
12 h for induction of TNF gene expression. The rapid time course
is consistent with release of pre-formed TNFa protein rather than
reflecting de novo cytokine synthesis, post-translational modifica-
tion, trafficking and externalization, suggesting the predominant
influence of vmiR88 and vmiR99 was independent of gene
silencing pathways. Additional support for non-RNAi function of
the novel vmiR88 and vmiR99 relates to their copy numbers, as
host cell miRNAs generally far exceed small RNA reads in HIV-
infected cells [14,15,32]. In general, the RNAi function of miRNA
is stoichiometrically dependent, since RNAi translational blockade
requires $100 miRNA copies for effective silencing of individual
genes by the mechanism of RNAi [44]. However, as HIV-derived
vmiR88 and vmiR99 can be released at low copy numbers, the
observed biological effects more likely represent activation of
alternate pathways (such as TLR8 signaling) that can provide
amplification in a signal cascade and stimulate physiologically
relevant responses resulting in cytokine release.
Detection of abundant vmiR-TAR in HIV-infected cells
associated with exosomes in the current study confirms reports
by other investigators [12,45], and validates our methodology.
Although abundant, the observation that vmiR-TAR did not
stimulate macrophage TNFa release suggests different regulatory
roles for HIV-derived miRNA. VmiR-TAR may influence cellular
apoptosis or enhance macrophage susceptibility to HIV infection
[16,46] through targeted gene silencing, although this was not
specifically investigated in the current study. Though the current
study focused on novel HIV vmiR88 and vmiR99, the potential
identification and role of other pro-inflammatory HIV-produced
miRNAs cannot be excluded and remains the focus of active
investigation. Furthermore, the potential role of other HIV-
produced miRNAs that may serve an antagonistic or anti-
inflammatory role cannot be excluded, and any RNAi influence
of novel vmiR88 or vmiR99 cannot be excluded, as these were not
specifically investigated in the current study. The potential
Figure 6. Working model of HIV-produced miRNA activation of bystander cells in HIV+ persons. This figure provides a working model
describing how HIV-produced miRNAs are encapsulated in exosomes and released from HIV-infected macrophages into the circulation. Host RNA
polymerases transcribe HIV genomic RNA, which is then exported into the cytoplasm and packaged into infectious virions. However, some HIV
transcripts can be processed in the host RNA interference pathway into mature viral miRNA. HIV miRNAs are packaged into multi-vesicular bodies and
released by macrophages encapsulated in exosomes. Exosomes are disseminated either locally or systemically to be taken up by bystander
macrophages, trafficking GU-rich vmiR88 and vmiR99 to the endosomal TLR8. Through this non-RNAi function of miRNAs that is distinct from the
well-established role of miRNAs in RNA interference, vmiR88 and vmiR99 induce TLR8-mediated inflammatory signaling pathway that leads to
downstream release of TNFa leading to chronic immune activation.
doi:10.1371/journal.pone.0106006.g006
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TNFa cannot be excluded, as the exosome preparations were not
specifically processed to remove HIV-1 virions [47]. However,
experiments using synthesized vmiR88 and vmiR99 suggest that
these molecules are sufficient for signaling resulting in induction of
macrophage TNFa release (in the absence of HIV-1 virions).
Moreover, abundant vmiRs were measured in exosomes from sera
of asymptomatic HIV+ persons even though they exhibit clinically
undetectable viral loads. We are investigating whether vmiR
uptake is more efficient depending on vehicle (exosome delivery
compared to synthetic LyoVec complexes) or cell type, since
uptake efficiency would affect the apparent dose of vmiR needed
for proinflammatory cell signaling leading to cytokine release.
Although novel HIV-produced vmiR88 and vmiR99 promote
macrophage TNFa release in vitro cell assays (current study) and
stimulates foam cell formation in vitro [35], whether this reflects
biological activity in vivo remains to be determined. We have
previously demonstrated that HIV ssRNA stimulates macrophages
via TLR8 (and not by TLR7) resulting in TNFa release [8]. We
report that HIV vmiR99 also stimulates the same response via
TLR8 in gene silencing experiments. Because TLR7 was not
specifically investigated in the current study, we cannot exclude
the possibility that vmiR99 may also interact with macrophage
TLR7 (or other TLRs). Finally, in addition to the intended vmiR-
specific blocking activity of antagomirs, our antagomir designs
were fully 29-O-methylated and might also serve as TLR8
antagonists, since in human PBMCs the related receptor TLR7
is inhibited by direct binding to alternating 29-O-methylated
ssRNA and dsRNAs [48,49].
Conclusions
This study demonstrates that HIV encoded miRNA, including
vmiRNA-TAR and two novel HIV miRNA, vmiR88 and
vmiR99, are detected in HIV-infected human macrophages, are
released by HIV-infected macrophages and are associated with
exosomes. Furthermore, mature vmiR88 and vmiR99 demon-
strate an important biological function other than RNAi function
and can directly stimulate signaling in macrophages that elicits
TNFa release, dependent on TLR8 and G+U content. The
detection of HIV vmiR88 and vmiR99 in the exosomal fraction of
sera from HIV+ persons and pro-inflammatory stimulation by
vmiR-associated exosomes raises the possibility that circulating
vmiR88 or vmiR99 can stimulate recipient macrophages in vivo,
and together with other circulating microbial TLR ligands such as
endotoxin may contribute to chronic immune activation (Fig. 6).
Furthermore, specifically targeting HIV-produced vmiR88 or
vmiR99 with molecules such as antagomirs may represent a novel
therapeutic strategy to limit chronic immune activation and the
progression of AIDS. HIV miRNAs may also serve as biomarkers
for future development as clinical diagnostics.
Acknowledgments
A preliminary account of this study was presented in part at the American
Thoracic Society International Meeting, May 2013, Philadelphia, PA and
Society for Leukocyte Biology, October 2013, Newport, RI and the
Conference on Retroviruses and Opportunistic Infections (CROI Foun-
dation and International Antiviral Society–USA), March 2014, Boston,
MA. We thank Elizabeth Vassar-Sternburg, Kristin Linnell, Ann Houg-
land, Xiomarra Guerra, Johanna Leary, Cynthia Peguero, Jose Munguia
and the BIDMC West Procedure Center staff for technical assistance with
research bronchoscopies. We thank Amy Janiak of the Molecular Biology
Core Facility (Dana-Farber Cancer Institute) for DNA sequencing.
Author Contributions
Conceived and designed the experiments: MAB SDT. Performed the
experiments: MAB HZ SCY. Analyzed the data: MAB. Contributed to the
writing of the manuscript: MAB HK SDT. Contributed clinical samples:
AA HK.
References
1. Bosinger SE, Sodora DL, Silvestri G (2011) Generalized immune activation and
innate immune responses in simian immunodeficiency virus infection. Curr
Opin HIV AIDS 6: 411–418.
2. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, et al. (2003)
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly
active antiretroviral therapy is associated with ongoing increased CD4 T cell
activation and turnover. J Acquir Immune Defic Syndr 33: 125–133.
3. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006)
Microbial translocation is a cause of systemic immune activation in chronic HIV
infection. Nat Med 12: 1365–1371.
4. Sodora DL, Silvestri G (2008) Immune activation and AIDS pathogenesis. AIDS
22: 439–446.
5. Silvestri G, Feinberg MB (2003) Turnover of lymphocytes and conceptual
paradigms in HIV infection. J Clin Invest 112: 821–824.
6. Hasegawa A, Liu H, Ling B, Borda JT, Alvarez X, et al. (2009) The level of
monocyte turnover predicts disease progression in the macaque model of AIDS.
Blood 114: 2917–2925.
7. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev
Cancer 6: 857–866.
8. Han X, Li X, Yue SC, Anandaiah A, Hashem F, et al. (2012) Epigenetic
regulation of tumor necrosis factor a (TNFa) release in human macrophages by
HIV-1 single-stranded RNA (ssRNA) is dependent on TLR8 signaling. J Biol
Chem 287: 13778–13786.
9. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, et al. (2012) An
unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes
neurodegeneration. Nat Neurosci 15: 827–835.
10. Virtue A, Wang H, Yang XF (2012) MicroRNAs and Toll-like receptor/
interleukin-1 receptor signaling. J Hematol Oncol 5: 66.
11. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes.
Proc Natl Acad Sci U S A 107: 6328–6333.
12. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, et al. (2005)
Identification of microRNAs of the herpesvirus family. Nat Methods 2: 269–276.
13. Yeung ML, Bennasser Y, Watashi K, Le SY, Houzet L, et al. (2009)
Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence
for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids
Res 37: 6575–6586.
14. Schopman NC, Willemsen M, Liu YP, Bradley T, van Kampen A, et al. (2012)
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs.
Nucleic Acids Res 40: 414–427.
15. Whisnant AW, Bogerd HP, Flores O, Ho P, Powers JG, et al. (2013) In-depth
analysis of the interaction of HIV-1 with cellular microRNA biogenesis and
effector mechanisms. MBio 4(2): e000193.
16. Narayanan A, Iordanskiy S, Das R, Van Duyne R, Santos S, et al. (2013)
Exosomes derived from HIV-1-infected cells contain trans-activation response
element RNA. J Biol Chem 288: 20014–20033.
17. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, et al. (2002) Long-
term survival and virus production in human primary macrophages infected by
human immunodeficiency virus. J Med Virol 68: 479–488.
18. Kinter AL, Poli G, Maury W, Folks TM, Fauci AS (1990) Direct and cytokine-
mediated activation of protein kinase C induces human immunodeficiency virus
expression in chronically infected promonocytic cells. J Virol 64: 4306–4312.
19. Klebanoff SJ, Mehlin C, Headley CM (1997) Activation of the HIV type 1 long
terminal repeat and viral replication by dimethylsulfoxide and related solvents.
AIDS Res Hum Retroviruses 13: 1221–1227.
20. Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, et al. (2012)
Modest nonadherence to antiretroviral therapy promotes residual HIV-1
replication in the absence of virological rebound in plasma. J Infect Dis 206:
1443–1452.
21. Vandergeeten C, Quivy V, Moutschen M, Van Lint C, Piette J, et al. (2007)
HIV-1 protease inhibitors do not interfere with provirus transcription and host
cell apoptosis induced by combined treatment TNF-a+TSA. Biochem
Pharmacol 73: 1738–1748.
22. Tachado SD, Li X, Bole M, Swan K, Anandaiah A, et al. (2010) MyD88-
dependent TLR4 signaling is selectively impaired in alveolar macrophages from
asymptomatic HIV+ persons. Blood 115: 3606–3615.
23. Tachado SD, Zhang J, Zhu J, Patel N, Koziel H (2005) HIV impairs TNFa
release in response to Toll-like receptor 4 stimulation in human macrophages in
vitro. Am J Respir Cell Mol Biol 33: 610–621.
Novel HIV-1 MiRNAs Stimulate TNFa Release
PLOS ONE | www.plosone.org 13 September 2014 | Volume 9 | Issue 9 | e10600624. Koziel H, Eichbaum Q, Kruskal BA, Pinkston P, Rogers RA, et al. (1998)
Reduced binding and phagocytosis of Pneumocystis carinii by alveolar
macrophages from persons infected with HIV-1 correlates with mannose
receptor downregulation. J Clin Invest 102: 1332–1344.
25. Garbati MR, Hays LE, Keeble W, Yates JE, Rathbun RK, et al. (2013) FANCA
and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1b in
macrophages. Blood 122: 3197–3205.
26. Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin CK, Jr., et al. (2010)
Palmitate and insulin synergistically induce IL-6 expression in human
monocytes. Cardiovasc Diabetol 9: 73.
27. Pfaffl MW (2001) A new mathematical model for relative quantification in Real-
Time RT-PCR. Nucleic Acids Res 29: e45.
28. Markham NR, Zuker M (2008) UNAFold: software for nucleic acid folding and
hybridization. Methods Mol Biol 453: 3–31.
29. Bo ¨hnlein S, Hauber J, Cullen BR (1989) Identification of a U5-specific sequence
required for efficient polyadenylation within the human immunodeficiency virus
long terminal repeat. J Virol 63: 421–424.
30. Das AT, Klaver B, Berkhout B (1999) A hairpin structure in the R region of the
human immunodeficiency virus type 1 RNA genome is instrumental in
polyadenylation site selection. J Virol 73: 81–91.
31. Forsbach A, Nemorin JG, Montino C, Mu ¨ller C, Samulowitz U, et al. (2008)
Identification of RNA sequence motifs stimulating sequence-specific TLR8-
dependent immune responses. J Immunol 180: 3729–3738.
32. Althaus CF, Vongrad V, Niedero ¨st B, Joos B, Di Giallonardo F, et al. (2012)
Tailored enrichment strategy detects low abundant small noncoding RNAs in
HIV-1 infected cells. Retrovirology 9: 27.
33. Klase Z, Winograd R, Davis J, Carpio L, Hildreth R, et al. (2009) HIV-1 TAR
miRNA protects against apoptosis by altering cellular gene expression.
Retrovirology 6: 18.
34. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T (2013) Structural
reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands.
Science 339: 1426–1429.
35. Bernard MA, Han X, Inderbitzin S, Agbim I, Zhao H, et al. (2014) HIV-derived
ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell
formation. PLoS ONE 9(8): e104039.
36. Berkhout B, Klaver B, Das AT (1995) A conserved hairpin structure predicted
for the poly(A) signal of human and simian immunodeficiency viruses. Virology
207: 276–281.
37. Klasens BI, Thiesen M, Virtanen A, Berkhout B (1999) The ability of the HIV-1
AAUAAA signal to bind polyadenylation factors is controlled by local RNA
structure. Nucleic Acids Res 27: 446–454.
38. Stroynowski I, Kuroda M, Yanofsky C (1983) Transcription termination in vitro
at the tryptophan operon attenuator is controlled by secondary structures in the
leader transcript. Proc Natl Acad Sci U S A 80: 2206–2210.
39. Yanofsky C (2000) Transcription attenuation: once viewed as a novel regulatory
strategy. J Bacteriol 182: 1–8.
40. Turnbough CL, Jr., Switzer RL (2008) Regulation of pyrimidine biosynthetic
gene expression in bacteria: repression without repressors. Microbiol Mol Biol
Rev 72: 266–300.
41. Wagschal A, Rousset E, Basavarajaiah P, Contreras X, Harwig A, et al. (2012)
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature
termination of transcription by RNAPII. Cell 150: 1147–1157.
42. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, et al. (2004)
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells.
Blood 104: 3257–3266.
43. Bennasser Y, Le SY, Benkirane M, Jeang KT (2005) Evidence that HIV-1
encodes an siRNA and a suppressor of RNA silencing. Immunity 22: 607–619.
44. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, (2007)
Endogenous microRNA can be broadly exploited to regulate transgene
expression according to tissue, lineage and differentiation state. Nat Biotechnol
25: 1457–1467.
45. Do ¨lken L, Perot J, Cognat V, Alioua A, John M, et al. (2007) Mouse
cytomegalovirus microRNAs dominate the cellular small RNA profile during
lytic infection and show features of posttranscriptional regulation. J Virol 81:
13771–13782.
46. Ouellet DL, Vigneault-Edwards J, Le ´tourneau K, Gobeil LA, Plante I, et al.
(2013) Regulation of host gene expression by HIV-1 TAR microRNAs.
Retrovirology 10: 86.
47. Schopman NC, van Montfort T, Willemsen M, Knoepfel SA, Pollakis G, et al.
(2012) Selective packaging of cellular miRNAs in HIV-1 particles. Virus Res
169: 438–447.
48. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, et al. (2007) 29-O-
methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15: 1663–1669.
49. Hamm S, Latz E, Hangel D, Mu ¨ller T, Yu P, et al. (2010) Alternating 29-O-
ribose methylation is a universal approach for generating non-stimulatory
siRNA by acting as TLR7 antagonist. Immunobiology 215: 559–569.
Novel HIV-1 MiRNAs Stimulate TNFa Release
PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e106006